RSV Vaccine 2025
Respiratory syncytial virus (RSV) made headlines this winter for its role in the tripledemic that, together with COVID-19 and flu, slammed many U.S. hospitals. But now there’s some good news related to RSV: On May 3, the Food and Drug Administration (FDA) gave its first-ever approval to a vaccine that protects against the dangerous condition. Each year, RSV is associated with 6,000 to 10,000 deaths of U.S. adults 65 and older, and as many as 160,000 hospitalizations for
that vulnerable group. It also kills hundreds of children under the age of 5.
View Report